Register for our free email digests:
Ortheon Medical LLC
Latest From Organon NV
Boehringer Ingelheim's Paola Casarosa explains that when her company partners with academia, it looks for the best way to mine that level of expertise rather than trying to fit the collaboration to a preferred deal model. Plus, our roundup includes three cancer-related deals and one for dry eye disease.
This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.
Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.
Putting Substance In “Substantial Evidence”: FDA Standards Take Center Stage In Rejection of Gepirone
Fabre-Kramer is asking FDA to reconsider its depression drug gepirone, nearly a decade after the agency rejected the application for the third time. The sponsor's case appears to be based on the hope that today's FDA will take a different view than the 2007 version of the agency.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.